Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis
Wei-Fu Lv,Kai-Cai Liu,Dong Lu,Chun-Ze Zhou,De-Lei Cheng,Jing-Kun Xiao,Xing-Ming Zhang,Zheng-Feng Zhang +7 more
TLDR
TACE can significantly improve local response, increase cumulative survival rate, and prolong the survival duration of patients with HCC and grades I/II PVTT, whereas the efficacy of TACE for patients with grades III/IV PVTT should be further verified, although their local responses were improved.Abstract:
Objectives To explore the efficacy and influencing factors of transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC) combined with portal vein tumor thrombosis (PVTT). Materials and methods The clinical data of 3,126 consecutive patients who suffered from advanced HCC and underwent TACE were retrospectively analyzed. A total of 685 patients had a combination of HCC and PVTT. Of these patients, 475 were treated with TACE (Group A) and 210 were given a supportive care (Group B). The local response and overall survival of the two groups were observed and compared, and the influencing factors were examined through Cox regression analysis. Results The median survival time and cumulative survival rate at 6, 12, and 24 months of Group A were higher than those of Group B (P=0.002). Multiple Cox regression analysis revealed that Child-Pugh classes and PVTT grades were the independent prognostic factors affecting a patient's survival. Stratified analysis demonstrated that the survival time of patients diagnosed with grades I/II PVTT and treated with TACE was superior to that of patients provided with supportive care (P=0.001), but the survival time of patients with grades III/IV PVTT with or without TACE did not significantly differ (P=0.662). Conclusion TACE can significantly improve local response, increase cumulative survival rate, and prolong the survival duration of patients with HCC and grades I/II PVTT, whereas the efficacy of TACE for patients with grades III/IV PVTT should be further verified, although their local responses were improved. Child-Pugh classes and PVTT grades are essential factors influencing patient prognosis.read more
Citations
More filters
Journal ArticleDOI
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west.
Jian Lu,Xiu-Ping Zhang,Bin-Yan Zhong,Wan Yee Lau,David C. Madoff,J. Davidson,Xiaolong Qi,Shu-Qun Cheng,Gao-Jun Teng +8 more
TL;DR: It is concluded that a personalised, data-driven approach to care with active management from a multidisciplinary team, as well as increased communication and collaboration between clinicians and researchers based in east and the west, could help to reduce the differences in management and optimise treatment strategies.
Journal ArticleDOI
Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis
Jungang Hu,Quan Bao,Guang Cao,Xu Zhu,Renjie Yang,Xinqiang Ji,Liang Xu,Kanglian Zheng,Weiliang Li,Baocai Xing,Xiaodong Wang +10 more
TL;DR: HAIC may significantly improve OS and provide better tumor control with mild side effects and preserved liver function in patients with advanced HCC with major PVTT compared to TACE/TAE treatment.
Journal ArticleDOI
Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides.
TL;DR: In this article, the authors discuss the management options of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) and show that adjuvant therapy and prompt management of recurrences holds the key to prolong overall survival (OS) and DFS.
Journal ArticleDOI
Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
Kai-Cai Liu,Ying-Hong Hao,Wei-Fu Lv,Wei-Dong Jia,Chu-Shu Ji,Chun-Ze Zhou,De-Lei Cheng,Shao-bao Xu,Zong-gen Gao,Ming-xue Su,Chang-sheng Shi +10 more
TL;DR: Compared with TACE treatment alone, TACE combined with sorafenib in BCLC-C stage HCC significantly improved disease control rate, TTP, and OS, and no significant increase in adverse reactions was observed.
Journal ArticleDOI
Dihydrodiosgenin inhibits endothelial cell-derived factor VIII and platelet-mediated hepatocellular carcinoma metastasis.
Manjiao Zhuang,Guang Xin,Zeliang Wei,Shiyi Li,Zhihua Xing,Chengjie Ji,Chengjie Ji,Junrong Du,Hai Niu,Wen Huang +9 more
TL;DR: This study found that pretreatment with dydio caused a significant inhibition of TCIPA and altered platelet function and coagulation FVIII level, resulting in decreased metastatic potential of HCC.
References
More filters
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
Management of hepatocellular carcinoma: An update
Jordi Bruix,Morris Sherman +1 more
TL;DR: The American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) were updated in 2010 as discussed by the authors.
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update
Jordi Bruix,Morris Sherman +1 more
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
Journal ArticleDOI
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
TL;DR: A group of experts developed a set of guidelines aimed at providing a common framework for the design of clinical trials in HCC and adapted the concept of viable tumor-tumoral tissue showing uptake in arterial phase of contrast-enhanced radiologic imaging techniques-to formally amend RECIST, referred to herein as the modified RECIST assessment (mRECIST).
Related Papers (5)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more